仙乐健康 reported revenue of ¥2.05B for the period ended 2026-06-30, +0.5% year on year. Net income was ¥0.14B, a 6.9% net margin on a 34.3% gross margin. The largest revenue line is 软胶囊 at 47% of the total. Free cash flow for the period was ¥0.11B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥2.05B | +0.5% |
| Gross profit | ¥0.70B | — |
| Operating income | ¥0.16B | — |
| Net income | ¥0.14B | +4.5% |
| Gross margin | 34.3% | Net margin 6.9% |
| Revenue Q/Q | +4.5% | — |
| Segment | Revenue | Share |
|---|---|---|
| 软胶囊 | ¥0.97B | 47.2% |
| 软糖 | ¥0.49B | 23.8% |
| 饮品 | ¥0.18B | 8.7% |
| 片剂 | ¥0.17B | 8.3% |
| 硬胶囊 | ¥0.10B | 4.7% |
| 粉剂 | ¥0.09B | 4.3% |
| 其他剂型 | ¥0.05B | 2.3% |
| 其他业务 | ¥0.01B | 0.7% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥1.35B | 65.7% |
| R&D | ¥0.06B | 3.1% |
| SG&A | ¥0.40B | 19.3% |
| Tax & other | ¥0.02B | 1.0% |
| Item | Amount |
|---|---|
| Total assets | ¥5.89B |
| Total liabilities | ¥2.84B |
| Shareholders' equity | ¥3.05B |
| Equity / assets | 51.8% |
| Operating cash flow | ¥0.21B |
| Capital expenditure | ¥0.10B |
| Free cash flow | ¥0.11B |
| Cash conversion (OCF / net income) | 135% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
壹网壹创 ・ 佳禾智能 ・ 米奥会展 ・ 贝斯美 ・ 钢研纳克 ・ 锦鸡股份 ・ 力合科技 ・ 泰和科技 ・ 矩子科技 ・ 广康生化 ・ 电声股份 ・ 斯迪克
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies